| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
4.53(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
773,595 |
| 52
Week Range: |
$23.37 - $33.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 581 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
35,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$815,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
15,666 |
15,666 |
89,488 |
206,962 |
| Total Sell Value |
$454,291 |
$454,291 |
$2,700,159 |
$6,056,962 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
3 |
3 |
7 |
12 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pops Richard F |
Director and CEO, Alkermes plc |
• • – |
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
218,551 |
1,271,432 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2024-02-08 |
4 |
D |
$26.77 |
$217,774 |
D/D |
(8,135) |
61,806 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2024-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
27,012 |
69,941 |
|
- |
|
| Parisi Samuel Joseph |
VP, Finance (Interim PAO)Offic |
• – – |
2024-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,900 |
|
-9% |
|
| Laurencin Cato T |
Director |
• • – |
2023-12-08 |
4 |
D |
$25.86 |
$25,860 |
D/D |
(1,000) |
15,169 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2023-12-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,163 |
16,169 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2023-08-03 |
4 |
D |
$27.63 |
$24,232 |
D/D |
(877) |
127,950 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2023-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,974 |
128,827 |
|
- |
|
| Alva Emily Peterson |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
19,722 |
|
- |
|
| Alva Emily Peterson |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,152 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
20,356 |
|
- |
|
| Wysenski Nancy |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,786 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
20,356 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,786 |
|
- |
|
| Mckeon Brian P |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
19,696 |
|
- |
|
| Mckeon Brian P |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,126 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
12,006 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
13,436 |
|
- |
|
| Daglio David Angelo Jr. |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
19,696 |
|
- |
|
| Daglio David Angelo Jr. |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,126 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
20,356 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
21,786 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
7,269 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2023-07-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,957 |
8,699 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
• • – |
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
20,783 |
|
- |
|
1496 Records found
|
|
Page 4 of 60 |
|
|
0.24 (0.98%) 
